Immunotherapies, biological and targeted therapies
Sponsored By
Cleveland ClinicBrain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

Search Term: Immunology, Biological therapies and targeted therapies
Please scroll down past the trials to see pages on this site about this topic!

  Treatment Location Last Updated
Details Phase II Clinical Trial of Hyperbaric Oxygenation in Conjunction with Radiotherapy and Temozolomide in Adults with Newly Diagnosed Glioblastoma Mineola, NY USA 06/18/2009
Details AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab, Leucovorin Rescue and Highly Active Antiretroviral Therapy Bethesda, MD USA 04/22/2009
Details Multiple Ascending Dose (MAD) Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Pediatric Patients With Advanced Solid Tumors. Bethesda, MD USA 04/22/2009
Details A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas New York, NY USA 04/21/2009
Details A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Bethesda, MD USA 04/21/2009
Details A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Cincinnati,, OH USA 04/21/2009
Details A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Columbus, OH USA 04/21/2009
Details A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Toronto, Ontario, CANADA 04/21/2009
Details A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma Winston-Salem, NC USA 04/21/2009
Details A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma Tampa, FL USA 04/21/2009
Details A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma Boston, MA USA 04/21/2009
Details A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma Baltimore, MD USA 04/21/2009
Details A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma Detroit, MI USA 04/21/2009
Details A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma Atlanta, GA USA 04/21/2009
Details A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma Cleveland, OH USA 04/21/2009
Details A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma Bethesda, MD USA 04/21/2009
Details A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma Philadelphia, PA USA 04/21/2009
Details A Feasibility Assessment and a Phase I/II Trial of MLN518 (Tandutinib) for Treatment of Patients with Recurrent Glioblastoma Birmingham, AL USA 04/21/2009
Details An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma Bethesda, MD USA 04/15/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Cincinnati, OH USA 04/06/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Cincinnati, OH USA 04/06/2009
Details Phase I/II study of sorafenib with radiation and temozolomide in newly diagnosed glioblastoma or gliosarcoma Houston, TX USA 04/03/2009
Details Phase II study of CDX-110 with radiation and temozolomide in patients with newly diagnosed glioblastoma multiforme Houston, TX USA 04/03/2009
Details Phase III, randomised, parallel Group, multi-centre study in recurrent glioblastoma patients to compare the efficacy of cediranib monotherapy and the combination of cediranib with lomustine to the efficacy of lomustine alone Houston, TX USA 04/03/2009
Details Phase I Pilot Study of HLA-A2-Restricted Synthetic Glioma Antigen Peptide Vaccine and Poly ICLC Vaccine in Young Patients With Newly Diagnosed Malignant or Intrinsic Brain Stem Glioma, Incompletely Resected Non-Brainstem High-Grade Glioma, or Recurrent Unresectable Low-Grade Glioma Pittsburgh, PA USA 03/16/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Dallas, TX USA 03/15/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Tampa, FL USA 03/15/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Summit, NJ USA 03/15/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Cleveland, OH USA 03/15/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Los Angeles, CA USA 03/15/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Columbus, OH USA 03/15/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Chicago, IL USA 03/15/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Ann Arbor, MI USA 03/15/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Minneapolis, MN USA 03/15/2009
Details Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer Rochester, NY USA 03/15/2009
Details The GLASS-ART Trial: A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Durham, NC USA 03/04/2009
Details The GLASS-ART Trial: A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme New York, NY USA 03/04/2009
Details The GLASS-ART Trial: A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Tampa, FL USA 03/04/2009
Details The GLASS-ART Trial: A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Los Angeles, CA USA 03/04/2009
Details The GLASS-ART Trial: A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme Omaha, NE USA 03/04/2009
Details A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 (MAb-425) in High Grade Gliomas Philadelphia, PA USA 02/12/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Chicago, IL USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Detroit, MI USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Los Angeles, CA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Durham, NC USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) San Francisco, CA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Charlottesville, VA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Cleveland, OH USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Cleveland, OH USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Hackensack, NJ USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Syracuse, NY USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Chicago, IL USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Los Angeles, CA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Boston, MA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Jacksonville, FL USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) New Haven, CT USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Buffalo, NY USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Salt Lake City, UT USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Columbus, OH USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Evanston, IL USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) New York, NY USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Palo Alto, CA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) New York, NY USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Philadelphia, PA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Houston, TX USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Iowa City, IA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Seattle, WA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) New York, NY USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) San Francisco, CA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Saginaw, MI USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Gainsville, FL USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) San Antonio, TX USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Orange, CA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Atlanta, GA USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Baltimore, MD USA 01/31/2009
Details Phase II Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM) (ACT III) Lansing, MI USA 01/31/2009
Details A Pilot Study to Evaluate the Effects of Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Adults with High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas Pittsburgh, PA USA 01/06/2009
Details A Phase II Trial of Thalidomide in combination with Temozolomide or CPT-11 in patients with recurrent anaplastic gliomas or glioblastoma multiforme Houston, TX USA 10/27/2008
Details Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and CMV Infection Umea, Sweden 10/09/2008
Details Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and CMV Infection Uppsala, Sweden 10/09/2008
Details Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and CMV Infection Solna, Stockholm, Sweden 10/09/2008
Details Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients with Recurrent Malignant Glioma Houston, TX USA 04/15/2008
Details A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma Houston, TX USA 04/15/2008
Details Phase 2, 2-part, multicenter, open-label study to evaluate the safety, tolerability, and efficacy of CT-322 (Angiocept™) monotherapy and combination therapy with irinotecan in patients with recurrent glioblastoma multiforme Houston, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Durham, NC USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Houston, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Los Angeles, CA USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma New York, NY USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma San Antonio, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Houston, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Madison, WI USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Pittsburgh, PA USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Boston, MA USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas New York, NY USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Durham, NC USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Houston, TX USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Los Angeles, CA USA 04/15/2008
Details A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas Boston, MA 04/15/2008
Details Phase I/II Study of GP96 Heat Shock Protein-Peptide Complex Vaccine in Patients With Recurrent or Progressive High-Grade Glioma San Francisco, CA USA 03/02/2008
Details A phase I/II Evaluation of Vaccination with Type-1 Dendritic Cells Pulsed With Multiple Peptides In the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas Pittsburgh, PA USA 03/02/2008
Details Phase I Study of Immunization With Autologous Tumor Lysate-Pulsed Dendritic Cells in Patients With Malignant Gliomas (Vaccine Therapy in Treating Patients With Malignant Glioma) Los Angeles, CA USA 03/02/2008
Details Chemotherapy, Radiation Therapy, and Vaccine Therapy With or Without Daclizumab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery Durham, NC USA 03/02/2008
Details Phase ll Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients With Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System Los Angeles, CA USA 03/02/2008
Details A Phase l Trial of Tumor Associated Antigen Pulsed Dendritic Cell Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma Los Angeles, CA USA 03/02/2008
Details Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients Los Angeles, CA USA 03/02/2008
Details Phase I Study of Glioma-Associated Antigen (GAA) Peptide-Pulsed Dendritic Cell Vaccination in Malignant Glioma Patients Los Angeles, CA USA 03/02/2008
Details A Phase l Trial of Surgical Resection With Gliadel Wafer Placement Followed by Vaccination With Dendritic Cells Pulsed With Tumor Lysate for Patients With Malignant Glioma Los Angeles, CA USA 03/02/2008
Details Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-Specific T-Cell Adoptive Transfer [ERaDICATe] Durham, NC USA 03/02/2008
Details Phase I/II trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine For Patients With Recurrent High Grade Glioma San Francisco, CA USA 10/03/2007
Details Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme Philadelphia, PA USA 08/26/2007
Details Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme Charleston, SC USA 08/26/2007
Details Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme Philadelphia, PA USA 08/26/2007
Details Determination of the In-Tumor-Concentration of Imatinib Mesylate (Gleevec) in Malignant Glioma After Oral Administration Baltimore, MD USA 08/20/2007
Details Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms New York, NY USA 08/20/2007
Details A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas Vista, CA USA 08/20/2007
Details A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas Chicago, IL USA 08/20/2007
Details Phase II Trial of Intralesional Adoptive Cellular Therapy of Glioblastoma With Interleukin-2-Stimulated Lymphocytes Newport Beach, CA USA 08/19/2007
Details Gliadel and Dendritic Cell Vaccine for Malignant Glioma Los Angeles, CA USA 08/18/2007
Details A Phase II Trial of Dendritic Cell Vaccine Pulsed with Tumor Lysate Followed by Temozolomide Upon Recurrence in Patients with Newly Diagnosed Glioblastoma Los Angeles, CA USA 08/18/2007
Details A Phase II Trial With Bevacizumab (Avastin) and Irinotecan (CPT-11) for Patients With Primary Brain Tumors and Progression After Standard Therapy Copenhagen, Denmark 08/18/2007
Details A Phase II Study of Bevacizumab (Avastin) in Combination With Metronomic Temozolomide (Temodar)for Recurrent Malignant Glioma Durham, NC USA 08/18/2007
Details Phase II Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients with Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System Los Angeles, CA USA 08/18/2007
Details Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Pittsburgh, PA USA 08/04/2007
Details Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Houston, TX USA 08/04/2007
Details Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Los Angeles, CA USA 08/04/2007
Details Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Madison, WI USA 08/04/2007
Details Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Boston, MA 08/04/2007
Details Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma New York, NY USA 08/04/2007
Details Open-label, Dose Confirmation and Dosimetry Study of Interstitial 131-I chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme (GBM) Tustin, CA USA 07/31/2007
Details A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labelled Chlorotoxin In Patients with Recurrent or Refractory Somatic and/or Cereberal Metastatic Solid Tumors Chicago, IL USA 06/04/2007
Details A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labelled Chlorotoxin In Patients with Recurrent or Refractory Somatic and/or Cereberal Metastatic Solid Tumors Birmingham, AL USA 06/04/2007
Details A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labelled Chlorotoxin In Patients with Recurrent or Refractory Somatic and/or Cereberal Metastatic Solid Tumors Cambridge, MA USA 06/04/2007
Details A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labelled Chlorotoxin In Patients with Recurrent or Refractory Somatic and/or Cereberal Metastatic Solid Tumors Grand Rapids, MI USA 06/04/2007
Details A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labelled Chlorotoxin In Patients with Recurrent or Refractory Somatic and/or Cereberal Metastatic Solid Tumors Dallas, TX USA 06/04/2007
Details Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma Winston-Salem, NC USA 05/01/2007
Details Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma Tampa, FL USA 05/01/2007
Details Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma Boston, MA USA 05/01/2007
Details Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma Baltimore, MD USA 05/01/2007
Details Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma Detroit, MI USA 05/01/2007
Details Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma Atlanta, GA USA 05/01/2007
Details Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma Cleveland, OH USA 05/01/2007
Details Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma Birmingham, AL USA 05/01/2007
Details Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma Philadelphia, PA USA 05/01/2007
Details Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma Tampa, FL USA 05/01/2007
Details Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma Chicago, IL USA 05/01/2007
Details Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma Detroit, MI USA 05/01/2007
Details Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma Durham, NC USA 05/01/2007
Details Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma Atlanta, GA USA 05/01/2007
Details Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma Boston, MA 05/01/2007
Details Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma Cleveland, OH USA 05/01/2007
Details Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme Lebanon, NH USA 05/29/2006
Details Iodine I 131 Monoclonal Antibody TNT-1/B (131I MOAB TNT-1/B), in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Detroit, MI USA 02/03/2006
Details Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer New York, NY USA 11/27/2005
Details Phase I Dose Escalation Study of Autologous Antigen-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas (e.g. Glioblastoma Multiforme, Anaplastic Astrocytoma) Los Angeles, CA USA 11/27/2005
Details Phase I Dose Escalation Study of Autologous Antigen-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas (e.g. Glioblastoma Multiforme, Anaplastic Astrocytoma) Los Angeles, CA USA 11/27/2005
Details Use of interferon for the treatment of gliomas of the brain and spine. Kelantan, Malaysia, MALAYSIA 11/26/2005
Details Thalomid™ and Carboplatin for the Treatment of Pediatric Brain Stem Glioma Baltimore, MD USA 11/26/2005
Details Thalomid™ and Carboplatin for the Treatment of Pediatric Brain Stem Glioma Minneapolis, MN USA 11/26/2005
Details Thalomid™ and Carboplatin for the Treatment of Pediatric Brain Stem Glioma Dayton, OH USA 11/26/2005
Details Thalomid™ and Carboplatin for the Treatment of Pediatric Brain Stem Glioma St. Paul, MN USA 11/26/2005
Details A Phase II Study of Pegylated Interferon Alfa-2b (Peg-Intron`) in Children with Diffuse Pontine Gliomas Bethesda, MD USA 11/26/2005
Details Adoptive IL-2 activated LAK cell intratumoral immunotherapy implant with adjuvant radiosurgery boost and naturopathic/nutritional immune enhancement. This is for newly diagnosed patients only. Newport Beach, CA USA 11/26/2005
Details Chemotherapy,radiotherapy and immunotherapy for brain tumors. Guangzhou, CHINA (PR) 11/26/2005
Details Phase I/II trial of ZD1839 (Iressa) in pediatric patients newly diagnosed with brain stem tumors or incompletely resected supratentorial malignant gliomas. Durham, NC USA 11/13/2005
Details A Phase I/II Study of Anti-Angiogenesis Therapy for Atypical and/or Unresectable Meningioma Chicago, IL 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Phoenix, AZ USA 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Iowa City, IA USA 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Nice, 06002, France 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Minneapolis, MN USA 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Lexington, KY USA 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Boston, MA USA 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection St. Louis, MO USA 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Brussels, Belgium 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Marseille, France 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection , Germany 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection , Germany 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Germany, 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection , Germany 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection , Netherlands 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection New York, NY USA 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Milwaukee, WI USA 11/13/2005
Details A Multicenter Phase II Study of TP-38 in Those Patients With Glioblastoma Multiforme Who Have Recurred or Progressed After Previous Resection and Radiation Therapy and Are Scheduled for Gross Total Resection Memphis, TN USA 11/13/2005
Details TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma(or Glioblastoma multiforme) Washington, DC USA 11/11/2005
Details TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma(or Glioblastoma multiforme) Boston, MA USA 11/11/2005
Details TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma(or Glioblastoma multiforme) Memphis, TN USA 11/11/2005
Details Phase I/II, two-arm, multicenter, dose escalation study of Oral AEE788 administered on a continuous once daily dosing schedule in adult patients with recurrent or relapsing glioblastoma. Los Angeles, CA USA 11/07/2005
Details Phase I/II, two-arm, multicenter, dose escalation study of Oral AEE788 administered on a continuous once daily dosing schedule in adult patients with recurrent or relapsing glioblastoma. Durham, NC USA 11/07/2005
Details Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Iowa City, IA USA 11/06/2005
Details Randomized Phase 2 with CpG-ODN in Malignant Glioblastoma Paris, France 11/06/2005
Details Randomized Phase 2 with CpG-ODN in Malignant Glioblastoma Paris, France 11/06/2005

(Relevance) Page Title - click title to go to the page!

  (0.7967)   Advanced Search
  (0.7742)   Brain Tumor Treatments: BCNU (Carmustine)
  (0.7742)   Brain Tumor Treatments: BCNU (Carmustine)
  (0.7742)   Brain Tumor Treatments: BCNU (Carmustine)
  (0.7742)   Toxin Therapy for Brain Tumors
  (0.7742)   High Dose Tamoxifen For Brain Tumors
  (0.7742)   Immunotherapies, biological and targeted therapies
  (0.7742)   Immunotherapies, biological and targeted therapies





Home | Brain Tumor Guide | Search | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Chat | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Gliadel® Wafer | Temodar®
Fundraising For Research | Unsubscribe | Contact Us | Doctors Address Book

IF YOU ARE USING A SCREEN READER, CLICK HERE
[Click HERE to open a Printer Friendly Version Of This Page!]

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsual Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites